

We Claim:

1. Use of antibodies for producing a vaccine for passive immunization against high molecular weight melanoma-associated antigen on malignant melanoma.
2. The use according to claim 1, characterized in that the antibodies are monoclonal antibodies.
3. The use according to claim 2, characterized in fact that the antibodies are 225.28S monoclonal antibodies.
4. The use according to any of the previous claims, characterized in that the antibodies are marker-free.
5. The use according to any of the previous claims, characterized in that the antibodies are nonconjugated.
6. The use according to any of the previous claims, characterized in that whole antibodies are use.
7. The use according to any of claims 1-5, characterized in that F(ab')₂ fragments are used.
8. The use according to any of the previous claims, characterized in that the use of the antibodies is effected together with another active substance.
9. The use according to claim 8, characterized in that the active substance is a monoclonal antibody, preferably an antibody against high molecular weight melanoma-associated antigen.
10. The use according to any of claims 8-10, characterized in that the active substance contains a radioactive component.
11. The use according to any of claims 8-10, characterized in that the active substance is a cytostatic.